EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pharmaceutical cost savings from the treatment of oncology patients in clinical trials

Borja Gómez Mediavilla, Paloma Lanza-León, Virginia Martínez Callejo, David Cantarero-Prieto, María Lanza Postigo, Matilde Salcedo Lambea, Yolanda Blanco Mesonero, María Ochagavia Sufrategui, Ignacio Durán, Carmen María Sarabia Cobo

Biomedical Journal · 2025

DOI: 10.1016/j.bj.2024.100742 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Journal, 2025. Verfasst von Borja Gómez Mediavilla und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology and Nanovaccines Research Gruop, Instituto de Investigación Valdecilla-IDIVAL, Santander, Spain. Hauptthemen laut MEDLINE: Neoplasms, Cost Savings, Clinical Trials as Topic, Drug Costs. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministerio de Sanidad, Consumo y Bienestar Social.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsCost SavingsClinical Trials as TopicDrug CostsAntineoplastic AgentsHumansMedical Oncology

Stichwörter der Autor:innen

Avoided costCancerClinical trialsCost savingDrugsInvestigational medicinal product

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Medical Oncology and Nanovaccines Research Gruop, Instituto de Investigación Valdecilla-IDIVAL, Santander, Spain.
  • Departamento de Economía, Universidad de Cantabria, Santander, Spain; Health Economics Research Group, Valdecilla Biomedical Institute Research - IDIVAL, Santander, Spain. Electronic address: bgomez@idival.org.
  • Department of Hospitalary Phramacy, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Departamento de Economía, Universidad de Cantabria, Santander, Spain; Health Economics Research Group, Valdecilla Biomedical Institute Research - IDIVAL, Santander, Spain.
  • Medical Oncology and Nanovaccines Research Gruop, Instituto de Investigación Valdecilla-IDIVAL, Santander, Spain; Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Department of Nursing, Universisty of Cantabria, Santander, Spain; Instituto de Investigación Valdecilla-IDIVAL, Santander, Spain.

Förderung

  • Ministerio de Sanidad, Consumo y Bienestar Social

Zitieren

APA

Gómez Mediavilla, B., Lanza-León, P., Martínez Callejo, V., Cantarero-Prieto, D., Lanza Postigo, M., Salcedo Lambea, M., Blanco Mesonero, Y., Ochagavia Sufrategui, M., Durán, I., & Sarabia Cobo, C. M. (2025). Pharmaceutical cost savings from the treatment of oncology patients in clinical trials. Biomedical Journal. https://doi.org/10.1016/j.bj.2024.100742

Vancouver

Gómez Mediavilla B, Lanza-León P, Martínez Callejo V, Cantarero-Prieto D, Lanza Postigo M, Salcedo Lambea M, et al. Pharmaceutical cost savings from the treatment of oncology patients in clinical trials. Biomedical Journal. 2025. doi:10.1016/j.bj.2024.100742

BibTeX
@article{GmezMediavilla2025,
  author = {Gómez Mediavilla, Borja and Lanza-León, Paloma and Martínez Callejo, Virginia and Cantarero-Prieto, David and Lanza Postigo, María and Salcedo Lambea, Matilde and Blanco Mesonero, Yolanda and Ochagavia Sufrategui, María and Durán, Ignacio and Sarabia Cobo, Carmen María},
  title = {Pharmaceutical cost savings from the treatment of oncology patients in clinical trials},
  journal = {Biomedical Journal},
  year = {2025},
  doi = {10.1016/j.bj.2024.100742}
}
Kostenlos starten →